The paper is part of the conversation

The human safety report by Stier and colleagues describes the clinical programme and the disappointing main weight-loss result. Tolerating treatment and benefiting from it are different findings.

The mouse study by Heffernan and colleagues reported increased use of fat as fuel and weight loss. It's part of the reason AOD-9604 attracted interest. Its results belong to mice, not people.

The rabbit knee experiment by Kwon and Park tested cartilage damage in an induced osteoarthritis model. It informs the regeneration discussion. It isn't evidence of repaired human joints, and it isn't a weight-loss study.

The early MOTS-c work by Lee and colleagues explored metabolic effects in cells and mice. It introduces the peptide and explains why researchers became interested in its role. Keep that setting attached to any claim.

The exercise paper by Reynolds and colleagues includes measurements of people's own MOTS-c after exercise, alongside treatment experiments in mice. A human observation in one part doesn't turn the mouse result into a human treatment result. FDA's MOTS-c review for its July 2026 meeting found no published human treatment studies of the peptide itself.

The human weight trial by Jastreboff and colleagues followed adults without diabetes for 72 weeks. It supports the weight-loss findings discussed here. The participants, lifestyle support and unwanted effects matter as much as the headline percentage when deciding what the result means.

The Zepbound (tirzepatide) prescribing information on DailyMed covers approved uses and safety warnings. It's a medicine's label, rather than another trial report. Its approval doesn't extend to compounded preparations or to a product with an unexplained nickname.

FDA's bulk-substance safety page, current as of April 22, 2026, lists AOD-9604 and MOTS-c among withdrawn nominations. The agency's safety concerns remain beside them. Withdrawal isn't clearance for compounding.

The compounding questions and answers explains the different compounding settings and manufacturing requirements. We use it on the MOTS-c page because a manufacturing claim and evidence of benefit are different things to check.

The explanation of compounded-drug risks makes the approval limit plain. Compounded medicines aren't FDA-approved, and FDA doesn't review their safety, effectiveness or quality before marketing. A prescription doesn't change that distinction or answer every research question.